Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis.
MDR-TB
TB
bedaquiline
delamanid
effectiveness
safety
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
01
02
2022
accepted:
20
02
2022
pubmed:
5
3
2022
medline:
15
12
2022
entrez:
4
3
2022
Statut:
ppublish
Résumé
Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. We reviewed the relevant scientific literature published up to January 20, 2022. The pooled success treatment rate with 95% confidence intervals (CI) was assessed using a random-effect model. We assessed studies for quality and bias, and considered P<0.05 to be statistically significant. After reviewing 626 records, we identified 25 studies that met the inclusion criteria, 22 observational and 3 experimental, with 1276 and 411 patients, respectively. In observational studies the overall pooled treatment success rate of DLM-containing regimens was 80.9% (95% CI 72.6-87.2) with no evidence of publication bias (Begg's test; P >0.05). The overall pooled treatment success rate in DLM and bedaquiline-containing regimens was 75.2% (95% CI 68.1-81.1) with no evidence of publication bias (Begg's test; P >0.05). In experimental studies the pooled treatment success rate of DLM-containing regimens was 72.5 (95% CI 44.2-89.8, P <0.001, I In MDR-TB patients receiving DLM, culture conversion and treatment success rates were high despite extensive resistance with limited adverse events.
Identifiants
pubmed: 35245659
pii: S1201-9712(22)00125-4
doi: 10.1016/j.ijid.2022.02.043
pmc: PMC9731904
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Nitroimidazoles
0
Oxazoles
0
Diarylquinolines
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
S90-S103Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare no conflicts of interest.
Références
Eur Respir J. 2013 Jun;41(6):1393-400
pubmed: 23018916
Respir Med. 2020 Jun;167:105956
pubmed: 32421540
J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):457-467
pubmed: 33347564
N Engl J Med. 2012 Jun 7;366(23):2151-60
pubmed: 22670901
Eur Respir J. 2020 Jan 16;55(1):
pubmed: 31619478
J Thorac Dis. 2017 Jul;9(7):2093-2101
pubmed: 28840010
Eur Respir J. 2020 Jul 23;56(1):
pubmed: 32703820
Eur Respir J. 2019 Dec 19;54(6):
pubmed: 31601711
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142
pubmed: 31729908
Pediatr Infect Dis J. 2020 Jun;39(6):512-513
pubmed: 32032176
Eur Respir J. 2018 Jun 14;51(6):
pubmed: 29650556
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Eur Respir J. 2017 May 21;49(5):
pubmed: 28529205
Eur Respir J. 2020 Jul 6;:
pubmed: 32631834
Eur Respir J. 2021 Mar 4;57(3):
pubmed: 33093123
Int J Tuberc Lung Dis. 2011 Jul;15(7):949-54
pubmed: 21682970
Biometrics. 1994 Dec;50(4):1088-101
pubmed: 7786990
J Infect Dev Ctries. 2021 Sep 29;15(9.1):7S-16S
pubmed: 34609955
Eur Respir J. 2017 Nov 9;50(5):
pubmed: 29122917
Int J Infect Dis. 2020 Sep;98:478-485
pubmed: 32640367
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751415
Eur Respir J. 2021 May 20;57(5):
pubmed: 33243846
Eur Respir J. 2018 Mar 22;51(3):
pubmed: 29545276
Int J Mol Sci. 2017 Feb 07;18(2):
pubmed: 28178199
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34764184
Emerg Infect Dis. 2017 Oct;23(10):
pubmed: 28767036
Antibiotics (Basel). 2020 Mar 23;9(3):
pubmed: 32209979
Antimicrob Agents Chemother. 2020 Dec 16;65(1):
pubmed: 33106258
Eur Respir J. 2020 Jul 9;56(1):
pubmed: 32457198
Pulmonology. 2021 Sep-Oct;27(5):403-412
pubmed: 33753021
Eur Respir J. 2016 Sep;48(3):938-43
pubmed: 27338197
Int J Tuberc Lung Dis. 2020 Dec 1;24(12):1265-1271
pubmed: 33317670
Pulmonology. 2021 Mar-Apr;27(2):151-165
pubmed: 33547029
Lancet. 2018 Sep 8;392(10150):821-834
pubmed: 30215381
Eur Respir J. 2015 May;45(5):1498-501
pubmed: 25700385
PLoS Med. 2018 Jul 11;15(7):e1002591
pubmed: 29995958
Eur Respir J. 2014 Sep;44(3):811-5
pubmed: 24833763
Clin Infect Dis. 2020 Dec 15;71(12):3252-3259
pubmed: 32521000
Eur Respir J. 2018 Jul 4;52(1):
pubmed: 29903862
Lancet Respir Med. 2019 Mar;7(3):249-259
pubmed: 30630778
Indian J Tuberc. 2019 Jan;66(1):184-188
pubmed: 30878066
Monaldi Arch Chest Dis. 2021 Jan 14;91(1):
pubmed: 33470080
Monaldi Arch Chest Dis. 2021 Jan 14;91(1):
pubmed: 33470081
Lancet Infect Dis. 2021 Jul;21(7):975-983
pubmed: 33587897
J Bras Pneumol. 2022 May 30;48(2):e20210384
pubmed: 35649043
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Pulmonology. 2020 Jul - Aug;26(4):233-240
pubmed: 32411943
Lancet Infect Dis. 2018 May;18(5):536-544
pubmed: 29452942
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0160821
pubmed: 34843388
Eur Respir J. 2021 Apr 8;57(4):
pubmed: 33833074
Eur Respir J. 2018 Jun 14;51(6):
pubmed: 29724920
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043
pubmed: 32361756
Clin Infect Dis. 2021 Nov 2;73(9):e3496-e3504
pubmed: 33079176
Eur Respir J. 2019 Jan 10;53(1):
pubmed: 30361253
Eur Respir J. 2021 Nov 11;58(5):
pubmed: 34446465
Eur Respir J. 2019 Nov 7;54(5):
pubmed: 31285308
Int J Infect Dis. 2020 Mar;92S:S15-S25
pubmed: 32032752